RxDoctor Payments Data

Richard Blanck, MD

Neurology · Lake Success, NYNPI 1548247125

Payments from drug & device makers

$130,413in general payments, 2019–2025

Across 1,666 payments — averaging $78.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$69K
  • Sanofi$32K
  • Novartis$4K
  • AbbVie$3K
  • Amgen$2K
  • AstraZeneca$2K
  • plus $18K from 54 others

What the payments were for

  • Consulting fees$22,07917%
  • Speaking & faculty fees$63,95849%
  • Travel & lodging$6,5175%
  • Food & beverage$37,85829%
  • Education$10%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen265$69,066
Sanofi70$32,313
Novartis187$3,751
AbbVie(2 entities)135$2,667
Amgen(2 entities)111$2,208
AstraZeneca(2 entities)74$2,203
EMD Serono, Inc.51$1,526
Genentech USA, Inc.90$1,346
Neurocrine Biosciences, Inc.36$1,260
Pfizer66$1,183
TG Therapeutics, Inc.20$987
SK Life Science, Inc.59$983
Lundbeck LLC55$695
Argenx US, Inc.18$656
Takeda Pharmaceuticals U.S.A., Inc.23$634
Grifols USA, LLC25$607
Teva Pharmaceuticals USA, Inc.30$604
Acadia Pharmaceuticals Inc32$536
Eisai Inc.16$523
Bristol Myers Squibb27$475
E.r. Squibb & Sons, L.L.C.5$394
Lilly USA, LLC21$361
Otsuka America Pharmaceutical, Inc.12$347
Amneal Pharmaceuticals LLC11$332
UCB, Inc.17$326
Scilex Pharmaceuticals Inc.10$297
Acorda Therapeutics, Inc22$261
Avanir Pharmaceuticals, Inc.10$233
Corium, LLC17$218
Biohaven Pharmaceutical Holding Company Ltd.13$214
Neurelis, Inc.4$208
Impel Pharmaceuticals Inc.8$196
Ipsen Biopharmaceuticals, Inc8$177
Johnson & Johnson8$173
Sunovion Pharmaceuticals Inc.10$169
Amylyx Pharmaceuticals, Inc.3$157
Kyowa Kirin, Inc.7$157
MDD US Operations, LLC8$154
Tanabe Pharma America, Inc.7$151
Biohaven Pharmaceuticals, Inc.7$144
CSL Behring5$116
Medtronic4$105
Penumbra, Inc.1$102
Genentech, Inc.1$99
Vertex3$85
Upsher-smith Laboratories LLC5$82
GE HealthCare4$80
Octapharma USA, Inc.4$79
Banner Life Sciences, LLC4$78
Catalyst Pharmaceuticals, Inc.3$61
Mallinckrodt Hospital Products Inc.3$60
Supernus Pharmaceuticals, Inc.3$49
Merz Pharmaceuticals, LLC2$48
Vanda Pharmaceuticals Inc.3$48
Abbott1$46
Assertio Therapeutics, Inc.3$44
Mallinckrodt Enterprises LLC2$40
Vertical Pharmaceuticals, LLC2$36
Strongbridge US Inc.2$36
Cycle Pharmaceuticals Inc1$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$130,413 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$281,970
Medicare patients
543
Services billed
1,769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate81$693,309
TecfideraDimethyl Fumarate30$471,111
VumerityDiroximel Fumarate36$358,591
Dimethyl Fumarate27$148,225
RebifInterferon Beta-1a/Albumin14$148,022
GlatopaGlatiramer Acetate40$127,731
Teriflunomide14$87,333
Glatiramer Acetate31$48,830
Dalfampridine ErDalfampridine63$36,087
Aimovig AutoinjectorErenumab-Aooe34$30,399
QuliptaAtogepant21$21,707
NuedextaDextromethorphan Hbr/Quinidine12$21,532
NamzaricMemantine Hcl/Donepezil Hcl15$12,912
Memantine Hcl167$7,237
DilantinPhenytoin Sodium Extended22$6,477

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Vumerity$69,066$829,70266 claims
Teva Pharmaceuticals USA, Inc.Copaxone$604$693,30981 claims
EMD Serono, Inc.Rebif$1,526$148,02214 claims
AbbVieQulipta, Namzaric$2,667$34,61936 claims
Avanir Pharmaceuticals, Inc.Nuedexta$233$21,53212 claims
PfizerDilantin$1,183$6,47722 claims
Upsher-smith Laboratories LLCTopiramate$82$69670 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Lake Success

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →